LITT for Ultra-early GBM Recurrence
Laser Interstitial Thermal Therapy for Ultra-Early, Pre-Radiotherapy Glioblastoma Recurrence
Insel Gruppe AG, University Hospital Bern
12 participants
Feb 6, 2026
INTERVENTIONAL
Conditions
Summary
Glioblastoma (GBM) remains aggressive despite standard therapy (surgery (CRET) + RT/CT). Over 40% of patients develop recurrence between surgery and pre-RT MRI, with median overall survival (OS) of 13.3m and 24.4m for patients with and without recurrence in pre-RT MRI, respectively. Reoperation is avoided as it delays adjuvant therapy. LITT offers a minimally invasive alternative that may: * Treat recurrence without delaying RT/CT * Potentially sensitize tumors to subsequent therapy This study tests if LITT can be practically integrated within the critical 1-week window between pre-RT MRI and radiotherapy initiation, maintaining the adjuvant schedule.
Eligibility
Inclusion Criteria12
- Histologically confirmed glioblastoma, IDH-wildtype, regardless of MGMT status
- ≥18 years of age
- CRET
- Karnofsky Performance Status (KPS) ≥70
- No contra-indication for radio-chemotherapy
- Scheduled for adjuvant radio-chemotherapy at University Hospital of Bern
- Able to provide informed consent
- No contra-indication for LITT
- No pregnancy or active breast-feeding
- No known coagulopathy independent of medication
- No dissemination or multifocal disease
- Patients lacking capacity to consent or considered vulnerable (e.g., minors, those under legal protection) are not included.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Patients undergoing MR-guided Laser Interstitial Thermal Therapy (LITT) between pre-RT MRI and RT.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07616986